Jacobs Levy Equity Management
TARA icon

Jacobs Levy Equity Management’s Protara Therapeutics TARA Stock Holding History

Jacobs Levy Equity Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$262K Buy
+50,255
New +$297K ﹤0.01% 892
2017
Q2 		– Sell
-1,807
Closed -$126K – 1013
2017
Q1 		$126K Buy
+1,807
New +$135K ﹤0.01% 842

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Jacobs Levy Equity Management's TARA Position: Q1 2026 in Review

Jacobs Levy Equity Management opened a new position in Protara Therapeutics (TARA) in Q1 2026: 50,255 shares worth $262K. The stake represents ﹤0.01% of the portfolio and ranks #892 among its holdings. This is a return to the name: Jacobs Levy Equity Management previously reported a position in TARA as recently as Q1 2017.

Jacobs Levy Equity Management first reported a position in TARA in Q1 2017 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

  • Jacobs Levy Equity Management held 50,255 shares of Protara Therapeutics worth $262K as of Q1 2026.
  • Protara Therapeutics was a new Jacobs Levy Equity Management position in Q1 2026.
  • Protara Therapeutics made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #892 holding.
  • Jacobs Levy Equity Management first reported a position in Protara Therapeutics in Q1 2017 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.